Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2019 Publisher: Novartis New Zealand Limited, PO Box 99102, Newmarket, AUCKLAND 1149 Telephone: 0800 354 335
Amoxicillin Trihydrate dried suspension 125 mg/5 ml, 250 mg/5 ml and 100 mg/ml (as amoxicillin).
| Pharmaceutical Form |
|---|
|
Ospamox powder for oral suspension: 125 mg/5 ml: Suspension, oral, powder for, white to yellowish colour. 250 mg/5 ml: Suspension, oral, powder for, white to yellowish colour. 500 mg/5 ml: Suspension, oral, powder for, white to yellowish colour. Ospamox Paediatric Drops 100 mg/ml: Suspension, oral, granules for, white to yellowish colour. |
125 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 125 mg.
250 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 250 mg.
500 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 500 mg.
Reconstituted suspension contains in 1 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 100 mg.
For the full list of excipients, see Section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Amoxicillin |
Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. |
| List of Excipients |
|---|
|
Ospamox powder for oral suspension: Guar gum, aspartame Ospamox Paediatric Drops: Sucrose |
Ospamox powder for oral suspension:
125 mg/5 ml: Bottle of 100 ml.
250 mg/5 ml: Bottle of 100 ml.
500 mg/5 ml: Bottle of 100 ml.
Ospamox Paediatric Drops 100 mg/ml:
Bottle of 30 ml with graduated dosing syringe.
Not all pack sizes and/or strengths may be currently marketed.
Novartis New Zealand Limited, PO Box 99102, Newmarket, AUCKLAND 1149
Telephone: 0800 354 335
Date of first approval: 30 September 2015.
| Drug | Countries | |
|---|---|---|
| OSPAMOX | Austria, Estonia, Hong Kong, Croatia, Lithuania, Nigeria, New Zealand, Poland, Romania, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
